Drug Design

"Drug Design" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include pharmacokinetics, dosage analysis, or drug administration analysis.

Descriptor ID	D015195
MeSH Number(s)	E05.295.500 H01.158.703.007.675.500 H01.181.466.675.500
Concept/Terms	Drug Design Drug Design Design, Drug Designs, Drug Drug Designs Drug Modeling Drug Modeling Drug Modelings Modeling, Drug Modelings, Drug

Below are MeSH descriptors whose meaning is more general than "Drug Design".

Analytical, Diagnostic and Therapeutic Techniques and Equipment [E]
Investigative Techniques [E05]
Drug Discovery [E05.295]
Drug Design [E05.295.500]
Natural Sciences [H]
Natural Science Disciplines [H01]
Biological Science Disciplines [H01.158]
Pharmacology [H01.158.703]
Chemistry, Pharmaceutical [H01.158.703.007]
Drug Discovery [H01.158.703.007.675]
Drug Design [H01.158.703.007.675.500]
Chemistry [H01.181]
Chemistry, Pharmaceutical [H01.181.466]
Drug Discovery [H01.181.466.675]
Drug Design [H01.181.466.675.500]

Below are MeSH descriptors whose meaning is related to "Drug Design".

Below are MeSH descriptors whose meaning is more specific than "Drug Design".

Drug Design
Polypharmacology

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Drug Design" by people in this website by year, and whether "Drug Design" was a major or minor topic of these publications.

Bar chart showing 74 publications over 23 distinct years, with a maximum of 9 publications in 2007

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1997	0	1	1
1998	0	1	1
1999	0	1	1
2001	0	1	1
2002	1	1	2
2003	0	1	1
2004	1	2	3
2005	1	0	1
2006	1	2	3
2007	3	6	9
2008	2	6	8
2009	0	1	1
2010	1	6	7
2011	2	4	6
2012	2	5	7
2013	3	1	4
2014	1	1	2
2015	3	1	4
2016	3	1	4
2017	1	1	2
2018	1	2	3
2019	1	1	2
2020	1	0	1

Below are the most recent publications written about "Drug Design" by people in Profiles.

Glasgow A, Glasgow J, Limonta D, Solomon P, Lui I, Zhang Y, Nix MA, Rettko NJ, Zha S, Yamin R, Kao K, Rosenberg OS, Ravetch JV, Wiita AP, Leung KK, Lim SA, Zhou XX, Hobman TC, Kortemme T, Wells JA. Engineered ACE2 receptor traps potently neutralize SARS-CoV-2. Proc Natl Acad Sci U S A. 2020 11 10; 117(45):28046-28055.

View in: PubMed
Wu D, Sinha N, Lee J, Sutherland BP, Halaszynski NI, Tian Y, Caplan J, Zhang HV, Saven JG, Kloxin CJ, Pochan DJ. Polymers with controlled assembly and rigidity made with click-functional peptide bundles. Nature. 2019 10; 574(7780):658-662.

View in: PubMed
Velagapudi UK, Langelier MF, Delgado-Martin C, Diolaiti ME, Bakker S, Ashworth A, Patel BA, Shao X, Pascal JM, Talele TT. Design and Synthesis of Poly(ADP-ribose) Polymerase Inhibitors: Impact of Adenosine Pocket-Binding Motif Appendage to the 3-Oxo-2,3-dihydrobenzofuran-7-carboxamide on Potency and Selectivity. J Med Chem. 2019 06 13; 62(11):5330-5357.

View in: PubMed
Bushra R, Rehman A, Ghayas S, Zafar F, Ali H, Shafiq Y, Khalid F, Khan MA, Hanif A, Mustapha O. Formulation design, characterization and optimization of cinitapride (1mg) immediate release tablets using direct compression technology. Pak J Pharm Sci. 2018 Nov; 31(6 (Supplementary):2725-2731.

View in: PubMed
Jain A, Utley L, Parr TR, Zabawa T, Pucci MJ. Tebipenem, the first oral carbapenem antibiotic. Expert Rev Anti Infect Ther. 2018 07; 16(7):513-522.

View in: PubMed
Panettieri RA, Pera T, Liggett SB, Benovic JL, Penn RB. Pepducins as a potential treatment strategy for asthma and COPD. Curr Opin Pharmacol. 2018 06; 40:120-125.

View in: PubMed
Klein-Szanto AJ, Bassi DE. Proprotein convertase inhibition: Paralyzing the cell's master switches. Biochem Pharmacol. 2017 09 15; 140:8-15.

View in: PubMed
Aka AA, Rappaport JA, Pattison AM, Sato T, Snook AE, Waldman SA. Guanylate cyclase C as a target for prevention, detection, and therapy in colorectal cancer. Expert Rev Clin Pharmacol. 2017 May; 10(5):549-557.

View in: PubMed
Gottfridsson C, Panfilov S, Ebrahimi A, Gigger E, Pollard C, Henderson S, Ambery P, Raichlen JS. Drug-induced blood pressure increase - recommendations for assessment in clinical and non-clinical studies. Expert Opin Drug Saf. 2017 Feb; 16(2):215-225.

View in: PubMed
Waldman SA, Terzic A. Managing Innovation to Maximize Value Along the Discovery-Translation-Application Continuum. Clin Pharmacol Ther. 2017 Jan; 101(1):8-12.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement